Noom Enters Longevity Health Space with Proactive Health Microdose GLP-1Rx Program Designed to Help Millions Address the Biomarkers Most Linked to Future …

New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing ...

Obesity expert reveals the best way to decide if GLP-1s are right for you

Expert Dr. Salas-Whalen reveals that body composition testing, not just the number on your scale, is key to knowing whether ...
MobiHealthNews

Noom taps Ash for at-home testing for GLP-1 microdosing program

Ash will provide at-home biomarker testing to Noom users to provide insights into key health markers linked to chronic ...

Ash Partners with Noom to Power Health Testing Infrastructure for Proactive Health Microdose GLP-1Rx Program

Ash provides the at-home testing operational backbone for Noom’s new Proactive Health Microdose GLP-1Rx Program ...
Medscape

GLP-1 Drugs Eyed as Tool to Address Alcohol Use Disorder

Researchers are studying whether these widely used weight-loss drugs may also be future treatments for alcohol abuse.

Novo to test if GLP-1 weight loss drugs can help curb addiction

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with ...
European Medical Journal

SABCS 2025: Tracking GLP-1 Use in Breast Cancer Care

The study analyzed electronic health records from 708,406 patients diagnosed with breast cancer between January 2011 and ...

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...